TP53 and neoplasm: Given this observation, IHC analyses of p53 on recurrent β1 integrin-deficient tumours indicated a distinct staining pattern between β1 integrin-proficient and -deficient tumours, where 22% of the β1 integrin-deficient tumours (3 out of 14 tumours) exhibited high nuclear p53 positivity (Fig. 4g).